Multiagent Intratumoral Immunotherapy Can Be Effective in A20 Lymphoma Clearance and Generation of Systemic T Cell Immunity

Simple Summary Immunotherapy has shown promise clinically, but resistance to therapies remains an issue. Using novel combinations of immunotherapies may help overcome these barriers. Here, we tested combinations of immunotherapy agents that were administered intratumorally using a mouse model of lymphoma. We show that combination treatment with multiple immune-modulating agents allowed for greater tumor control and induced tumor-specific long-term immunological memory that was T cell dependent. Combination treated animals showed modest alterations in immune cell subsets in lymphoid tissues and had increased immune infiltration to tumors 24 h after treatment. Future studies should evaluate the impact of other immunotherapy combinations on a variety of tumor types. Abstract The use of immunotherapies has shown promise against selective human cancers. Identifying novel combinations of innate and adaptive immune cell-activating agents that can work synergistically to suppress tumor growth and provide additional protection against resistance or recurrence is critical. The A20 murine lymphoma model was used to evaluate the effect of various combination immunotherapies administered intratumorally. We show that single-modality treatment with Poly(I:C) or GM-CSF-secreting allogeneic cells only modestly controls tumor growth, whereas when given together there is an improved benefit, with 50% of animals clearing tumors and surviving long-term. Neither heat nor irradiation of GM-CSF-secreting cells enhanced the response over use of live cells. The use of a TIM-3 inhibitory antibody and an OX40 agonist in combination with Poly(I:C) allowed for improved tumor control, with 90% of animals clearing tumors with or without a combination of GM-CSF-secreting cells. Across all treatment groups, mice rejecting their primary A20 tumors were immune to subsequent challenge with A20, and this longstanding immunity was T-cell dependent. The results herein support the use of combinations of innate and adaptive immune activating agents for immunotherapy against lymphoma and should be investigated in other cancer types.

[1]  Richard J. Simpson,et al.  Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway , 2022, PloS one.

[2]  D. Czerwinski,et al.  Intratumoral immunotherapy relies on B and T cell collaboration , 2022, Science Immunology.

[3]  D. Dingli,et al.  Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma , 2022, Blood advances.

[4]  D. Czerwinski,et al.  Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer. , 2022, Cancer Research.

[5]  A. Titov,et al.  Knowns and Unknowns about CAR-T Cell Dysfunction , 2022, Cancers.

[6]  D. Hanahan Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[7]  P. Allavena,et al.  Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity , 2021, Journal for ImmunoTherapy of Cancer.

[8]  P. Pérez-Galán,et al.  Immunotherapies in Non-Hodgkin’s Lymphoma , 2021, Cancers.

[9]  Z. Berneman,et al.  A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy , 2021, Journal of Experimental & Clinical Cancer Research.

[10]  M. Babjuk,et al.  100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19 , 2021, Nature Reviews Urology.

[11]  I. Melero,et al.  Intratumoural administration and tumour tissue targeting of cancer immunotherapies , 2021, Nature Reviews Clinical Oncology.

[12]  A. Naranjo,et al.  Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 , 2021, Clinical Cancer Research.

[13]  H. Sultan,et al.  Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration , 2020, Journal for ImmunoTherapy of Cancer.

[14]  A. Anderson,et al.  Tim-3 finds its place in the cancer immunotherapy landscape , 2020, Journal for immunotherapy of cancer.

[15]  Kongming Wu,et al.  Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 , 2019, Molecular Cancer.

[16]  R. Wilkinson,et al.  Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies , 2019, Journal of Immunotherapy for Cancer.

[17]  B. Heyman,et al.  New developments in immunotherapy for lymphoma , 2018, Cancer biology & medicine.

[18]  W. Loging,et al.  Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial , 2018, Clinical Cancer Research.

[19]  A. Naranjo,et al.  A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 , 2018, Front. Immunol..

[20]  B. Fox,et al.  Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40 , 2017, Clinical Cancer Research.

[21]  R. Ponce,et al.  Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade , 2017, Clinical Cancer Research.

[22]  J. Vermorken,et al.  Immunotherapy in head and neck cancer: aiming at EXTREME precision , 2017, BMC Medicine.

[23]  J. Wolchok,et al.  Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells , 2017, Science Immunology.

[24]  Ana C Anderson,et al.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.

[25]  M. Mcnamara,et al.  OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal , 2015, Front. Oncol..

[26]  D. Schrijvers,et al.  Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. , 2015, Pharmacology & therapeutics.

[27]  S. Hahn,et al.  Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD , 2014, Bone Marrow Transplantation.

[28]  Marco Antonio Ayala García,et al.  The Major Histocompatibility Complex in Transplantation , 2012, Journal of transplantation.

[29]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[30]  R. Tibshirani,et al.  In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[32]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[33]  A. Bossler,et al.  Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma , 2006, Journal of immunotherapy.

[34]  M. Mbow,et al.  A pathway analysis of poly(I:C)-induced global gene expression change in human peripheral blood mononuclear cells. , 2006, Physiological Genomics.

[35]  Xinchun Chen,et al.  Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  M. Graner,et al.  Chaperone-rich cell lysates, immune activation and tumor vaccination , 2006, Cancer Immunology, Immunotherapy.

[37]  I. O-Sullivan,et al.  Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer , 2005, Cancer Gene Therapy.

[38]  H. Feng,et al.  Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. , 2001, Blood.

[39]  L. He,et al.  Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  B. Blazar,et al.  Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[41]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Benacerraf,et al.  Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse , 1959, Nature.